MarginsXMarginsX
Home › Markets › Health Care › CGEN

Compugen Ltd. (CGEN)

CGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.04
-2.86% on the day
Market cap
$193.0M
Micro cap
Revenue · 2025
$72.8M
+161.1% on 2024
Net income · 2025
$35.3M
48.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1119774/000117891326000663/0001178913-26-000663-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCGEN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryIsrael
IPO year2000
SEC CIK0001119774
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$72.8M
Net income$35.3M
Operating income$31.3M
Net margin48.6%
Operating margin43.1%
Revenue growth+161.1%
Cash$90.6M
Total assets$156.6M
P/E (computed)5.5×
P/S (computed)2.7×

Warning signs

Cash runway
Cash-flow positive
$90.6M cash at December 31, 2025
Share count, 1 year
+5.6%
2024-12-31 to 2025-12-31 · +9.2% over 3 years
Going-concern doubt
No
20-F filed March 2, 2026
Insider net buying, 12 months
-$118K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-02
Cash and burn$90.6M cash; operating cash flow $7.9M a quarter.Report 2025-12-31
Shares outstanding94,553,191 (2025-12-31); 89,541,246 a year earlier; 86,624,643 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKost Forer Gabbay & Kasierer, Tel Aviv, IsraelPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $118K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$72.8M$35.3M$31.6M$90.6MNo debt tags$72.8M20-F 2026-03-02
FY 2024
2024-12-31
$27.9M-$14.2M$49.6M$18.2MNo debt tags$27.9M20-F 2026-03-02
FY 2023
2023-12-31
$33.5M-$18.8M-$35.9M$13.9MNo debt tags$33.5M20-F 2026-03-02
FY 2022
2022-12-31
$7.5M-$33.7M-$34.1M$11.1MNo debt tags$7.5M20-F 2025-03-04
FY 2021
2021-12-31
$6.0M-$34.2M-$22.7M$7.8MNo debt tags$6.0M20-F 2024-03-05
FY 2020
2020-12-31
$2.0M-$29.7M-$28.3M$7.1MNo debt tags$2.0M20-F/A 2023-08-23
FY 2019
2019-12-31
Not filed-$27.3M-$27.9M$9.2MNo debt tagsNeeds four quarters20-F 2022-02-28
FY 2018
2018-12-31
$17.8M-$22.6M-$13.3M$5.9MNo debt tags$17.8M20-F 2021-02-25

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentF-32026-05-18
Latest annual report20-F2026-03-02
Latest quarterly / interim6-K2026-11-09

Source: SEC EDGAR submissions feed, 608 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.1%
1 month+6.1%
3 months-12.9%
Year to date+37.3%
1 year+27.3%
From 52-week high-32.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ARTVArtiva Biotherapeutics Inc.$3.96-1.25%$195.8M
LCTXLineage Cell Therapeutics Inc.$0.7951-13.07%$201.1M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M
IKTInhibikase Therapeutics Inc.$1.45-4.61%$203.4M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M
CABACabaletta Bio Inc.$1.11-13.28%$239.4M
STROSutro Biopharma Inc.$9.32-5.09%$154.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier